» Lung Cancer

Lung Cancer

GALAXY-2 TRIAL; PROTOCOL 9090-14:RANDOMIZED, PHASE 3 STUDY OF GANETESPIB IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG ADENOCARCINOMA
This is an open-label, randomized Phase 3 study of patients with advanced (Stage IIIB/IV) non-small cell lung cancer of adenocarcinoma histology. (Histology is the microscopic study of the structure of biological tissues using special staining techniques and microscopy)  Eligible study participants must have not responded to only one prior systemic therapy for advanced non-small cell lung cancer. Eligible study participants will be randomized to receive either Ganetespib in combination with Docetaxel or Docetaxel alone with the study comparing the effectiveness of Ganetespib in combination with Docetaxel versus Docetaxel alone
Principal Investigator:  Peter Graze, M.D. (443) 481-4884
Research Staff: Venita Crawford, BSN (443) 481-4393 / Steven DeMartino, CCRC (443) 481-4390
Website: http://clinicaltrials.gov/ct2/show/NCT01798485?term=galaxy+2&rank=1

CALGB-140503: A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (</=2cm) Peripheral Non-Small Cell Lung Cancer
The purpose of this study is to test a different way of doing surgery for lung cancer in patients who have small tumors with no evidence of spread. Recent studies have questioned whether removing a larger portion of the lung containing the tumor offers much better control of the cancer than removing a smaller section of the lung. The purpose of this clinical trial is to look at whether removal of a small section of lung (called a sublobar resection) is equal to a lobectomy (a larger surgery which takes out an entire section or ‘lobe’ of the lung, or about one-quarter to one-half of one lung, depending on which lobe is taken out). This clinical trial will be studying the overall effects (good and/or bad) of a sublobar resection (smaller segment of your lung) compared to a lobectomy (entire lobe of your lung).
Website: http://clinicaltrials.gov/ct2/show/NCT00499330?term=calgb+140503&rank=1
Principal Investigator:  Stephen Cattaneo, M.D.   (443)- 481-3366
Research Staff:  Steven DeMartino, CCRC, CRT, RPFT, AEC (443) 481-4390

Our Studies